Brand Name | Status | Last Update |
---|---|---|
lumizyme | Biologic Licensing Application | 2025-01-10 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
glycogen storage disease type ii | Orphanet_365 | D006009 | E74.02 |
Expiration | Code | ||
---|---|---|---|
alglucosidase alfa, Myozyme, Genzyme Corporation | |||
2113-04-28 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glycogen storage disease type ii | D006009 | Orphanet_365 | E74.02 | 2 | 10 | 6 | 13 | 23 | 51 |
Glycogen storage disease | D006008 | — | E74.0 | 2 | 10 | 6 | 11 | 10 | 36 |
Glycogen storage disease type iii | D006010 | Orphanet_366 | E74.03 | 1 | 2 | 2 | 7 | 3 | 15 |
Deficiency diseases | D003677 | EFO_1001067 | E63 | 1 | 4 | 2 | 1 | 1 | 8 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 2 | — | 2 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 2 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Disease | D004194 | EFO_0000408 | R69 | 1 | 7 | 4 | — | 5 | 14 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Metabolic diseases | D008659 | EFO_0000589 | E88.9 | 1 | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Muscular diseases | D009135 | EFO_0002970 | G72.9 | — | — | — | — | 1 | 1 |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Mucopolysaccharidoses | D009083 | — | E76.3 | — | — | — | — | 1 | 1 |
Mucopolysaccharidosis i | D008059 | — | E76.0 | — | — | — | — | 1 | 1 |
Mucopolysaccharidosis ii | D016532 | — | E76.1 | — | — | — | — | 1 | 1 |
Drug common name | Alglucosidase alfa |
INN | alglucosidase alfa |
Description | Alglucosidase alfa, sold under the brand name Myozyme among others, is an enzyme replacement therapy (ERT) orphan drug for treatment of Pompe disease (Glycogen storage disease type II), a rare lysosomal storage disorder (LSD).
Chemically speaking, the drug is an analog of the enzyme that is deficient in patients affected by Pompe disease, alpha-glucosidase. It is the first drug available to treat this disease.
|
Classification | Enzyme |
Drug class | enzymes |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201824 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB01272 |
UNII ID | DTI67O9503 (ChemIDplus, GSRS) |